Depression measurement in cancer care is complex and inconsistent. It is difficult for investigators to select the best-performing tool. We conducted a meta-review to integrate the findings of reviews of patient-report depression measures used as screeners or case-finders in oncology. We searched Medline, PsycINFO, EMBASE and grey literature from 1999-2014. We identified 19 reviews representing 372 primary studies assessing more than 50 depression measures. We used 11 highquality reviews to guide our analysis, which was organized by measurement goal and target population. The Hospital Anxiety Depression Scale was the most recommended, and criticized, depression screener. Few reviews evaluated casefinding performance or measure responsiveness, or measure suitability for particular populations. This meta-review demonstrates that the available measure selection advice is conflicting. By being fully cognizant of the benefits and limitations of depression measurement, investigators can improve the accuracy of their data and achieve more sophisticated interpretations of their findings.
Introduction
Psycho-oncology has seen an exponential rise in research documenting the prevalence, measurement and experience of depression in cancer. 3, 4 MedLine records that 'depression' and 'cancer' were addressed together in an average of 192 citations/year in the 1980's, rising to an average of >1000 citations/year between 2006-2015. 5, 6 Mirroring this rise, clinicians and researchers have utilized numerous patient-reported outcome measures to assess depression in individuals affected by cancer. 4, 7, 8, 9 Unrecognized and untreated depression can have deleterious implications for long term quality of life, 11, 12 treatment adherence 13 health service use, 14, 15 requests for death, 11 and mortality. [16] [17] [18] Opinion leaders therefore often recommend that all patients be evaluated for depressive symptoms at regular intervals across the trajectory of cancer care. 12 Accurate and timely measurement of depression can ensure that the prevalence of depression across populations and stages is neither under-nor over-estimated. 19, 20 This data is needed to inform clinical practice and the allocation of appropriate resources to psychosocial services. 3, 19 Available depression measures, however, yield differing data, 21 with one metaanalysis of 211 studies, using only 4 different depression measures, reporting a range of 8% to 24% cancer patients affected by depression. 22 It is not possible to elucidate whether this variability is due to actual differences in depression prevalence across cancer types or stages, is an artefact of the instrument used in each study, 22 or is a function of each study's characteristics (eg, sample size and representativeness). 6, 23 The use of a wide range of depression measures in clinical practice and research across studies has prevented simple cross-population and crosscultural comparisons. 7, 24 Also lost has been the ability to pool data, 8 and to compare outcomes across cancer types, 22 across time, 8 and across disease stages. 24 Numerous reviews of depression measures, as well as evaluation tools to assess measure quality, are available. Available reviews however differ in focus (eg, providing a generic summary, or systematically appraising evidence) and methods (eg, their search, appraisal, synthesis, and analysis). 25 The IPOS Research
Committee therefore conducted a meta-review (an 'overview of reviews' or reported separately from the performance of the complete measure. Reviews assessing outcome measures for specific cancer diagnoses (eg, breast cancer-specific measures) were also eligible, as were reviews assessing 'ultra-short' (1-4 items) and 'short' (5-20 items) instruments. 4 Types of reviews: We included published systematic (as defined by the PRISMA Statement; with or without meta-analyses) 28 and narrative reviews summarizing data collected from adults (aged 18+ years) diagnosed with any type of cancer, at any stage of the cancer experience (including palliative care and survivorship). Given the evidence that 'grey literature' plays an important role in guiding policy and practice, 30, 31 we also included reviews published in reports, discussion papers, briefings, and practice guidelines. 30 ,31 Reviews of measures used for screening (ie, to 'rule-out' patients without depression with minimal missed cases [false negatives]) 7 ,
case-finding (ie, to 'rule in' those who have depression with minimal false positives) 7 and assessment (ie, to determine the extent of depressive symptoms) were eligible.
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Exclusions: We excluded primary studies and reviews of non-questionnaire measures, such as face-to-face or telephone-delivered clinical interviews. There is a lack of depression research 33-36 in non-English speaking populations, however we restricted the meta-review to those published in English because expert review was not possible in other languages and translation was beyond the scope of the project.
We excluded other related domains, such as sadness, grief, suicidal ideation, melancholy, hopelessness, demoralization, adjustment disorder, and quality of life.
We excluded measures of generalized 'distress' due to their lack of specificity in terms of psychological morbidity, unless they were specifically evaluated as depression screeners or case-finders. 37 We also excluded reviews on individuals without a cancer diagnosis (eg, those at increased risk of cancer, partners, caregivers, and family members). When multiple reviews published by the same first author were captured, we utilized the article with the highest quality (defined by the PRISMA statement), unless the reviews addressed substantively different research case-finding tools, or iii) on their capacity to detect change (table 1) . We extracted the following data for screening tools: sensitivity and specificity (pooled or weighted), screening utility index, recommended 'cut-point' scores, and the review's recommendations. For articles that did not report summary sensitivity and specificity scores, we calculated medians and ranges of scores where possible. Data collected from reviews assessing case-finding capacity included: case-finding area under the curve (AUC) and positive utility index (UI+). Data gathered from reviews assessing capacity to detect change included: weighted score for responsiveness and effect sizes detected.
Critical appraisal (Step 3: 'Evaluating the quality of the evidence 27 )
CEW and EGR independently appraised the captured reviews using the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement criteria, 28 supplemented by the PRISMA Explanation and Elaboration document.
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When the investigators disagreed on any assessment, the issue was resolved through discussion with each other or with all authors. We decided, a priori, to focus our analysis on reviews that met 20 or more of the 27 PRISMA criteria because a recent assessment of the quality of PRISMA reporting in 236 reviews showed that approximately 70% of reviews meet 20 of the 27 PRISMA criteria. 40 Only measures recommended by at least one high-scoring review were considered as possible candidate measures suitable for detailed assessment. Narrative reviews were not critically appraised because their purpose and methods differ from systematic reviews.
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Results (Step 4: Analyzing the outcomes 27 )
We identified 19 eligible reviews with good inter-rater reliability, including 12 systematic and 7 narrative reviews (figure 1). The captured reviews represented 372 original studies and assessed more than 50 depression measures. The Medline-7 EMBASE-PsychInfo search was most effective, yielding 78·9% sensitivity (15/19 eligible reviews were captured with these searches) and 10·3% specificity (15 eligible articles were captured out of 145 abstracts). Reviews originated from the United States (n=8), the United Kingdom (n=6), Australia (n=3), Canada (n=1), and the Netherlands (n=1), and focused on mixed cancer diagnoses, or on a specific cancer population (eg, older patients 11, 42 ). The goals of each review varied. Nine reviews assessed the suitability of depression measures as screening tools, 1, 4, 5, 7, 8, 19, 22, 43, 44 while three assessed their suitability for case-finding. 7, 43, 44 Several reviews examined appropriate cut-points of specific measures, 8, 19, 45, 46 while others examined their usefulness in particular populations (eg, geriatric patients 11, 42 ).
One review assessed the responsiveness of depression measures in detecting the effect of psychological interventions. 5 One review assessed the performance of measures across five stages in the cancer trajectory, 8 while others focused on mixed diagnoses and treatment stages. 3, [5] [6] [7] 19, 20, 22, [43] [44] [45] [46] [47] Critical appraisal Table 2 summarizes the critical appraisal of each systematic review. All systematic reviews provided a sound rationale, a structured summary of findings, a description of their objectives and some discussion of findings (n=12). The PRISMA criteria least likely to be met were assessing the risk of bias within and across studies (four reviews assessed bias within studies 4, 7, 19, 22 and four assessed bias across studies 4, [43] [44] [45] ). Five reviews failed to acknowledge their limitations and no review provided review protocol/registration details, suggesting that protocol registration for reviews
is not yet common practice. 48 Eleven of the 12 systematic reviews met at least 20 of the PRISMA criteria. The findings of high scoring reviews are summarized in Tables   3-5. Tables 6 and 7 present the findings of lower scoring systematic reviews and the narrative reviews.
Aggregation of meta-review results (summary of high scoring reviews' recommendations)
Screening
The Hospital Anxiety and Depression Scale (HADS) was the most widely evaluated measure, with nine reviews assessing the HADS against other measures, 1, 4, 5, 7, 22, 42, 43 or alone. 19, 44 Positive features reported included its popularity (enabling cross-study 8 comparisons), 6, 8 and its ability to perform adequately across different stages of the cancer trajectory. 8 The HADS was described as performing well in identifying major depression within pre-treatment (with a cut-point of 7 for the HADS-Depression subscale [HADS-D]) and post-treatment populations (cut-point between 9 and 11 for HADS-D). 8 The most commonly-used threshold to determine depression prevalence during active treatment was a subscale score of 8 or above, 8, 19, 22 although this cutpoint was poorly supported in one review. 19 Each of the HADS subscales received moderate screening utility index scores for depression in one review (ranging from 0·65-0·71), 7 although these figures vary substantially across reviews. 7, 44 Several reviews converged on the limitations of the HADS, highlighting the differing performance between the HADS-Total scale (HADS-T), the HADSAnxiety subscale (HADS-A), and the HADS-D, 7 and the variability in recommended cut-points (ranging from 4 to 11). 4, 6, 8, 15, 19 Mitchell and colleagues also suggested that the HADS-T or HADS-A (rather than the HADS-D) could be used as the first choice for a depression screening measure. 44 HADS-A may also perform as well as HADS-T in identifying depression in palliative care, 1 although four reviews argued that the HADS was least suited for advanced cancer patients and for those receiving palliative care. 1, 4, 7, 8 Several reviews assessed the screening performance of the Beck Depression Inventory (BDI), and/or its variations (the BDI-II and the BDI-short form, BDI-SF). 1, 4, 5, 7, 8, 15, 22, 42, 43 In each case, the BDI's performance was considered in comparison with other measures. Reviews assessed the BDI favourably, highlighting its generalizability across cancer types and disease stages, 4 its adequate screening performance 7 and its potential usefulness in older patients. 42 One review described the BDI as 'excellent' for a long measure, due to its good reliability and validity. 4 Several reviews noted that the BDI has appropriate sensitivity and specificity, 1, 4, 7, 8 although some evidence suggests it has poorer specificity before and after cancer treatment. 8 The BDI, however, is limited somewhat by its length (21 items), reducing its acceptability. 4, 43 It also has a longer recall period (two weeks), potentially limiting its usefulness in some contexts. 42 The BDI has also been criticized for including items with a somatic emphasis. 5 The BDI-SF, with only 13 9 items may address some of these limitations; however, it may not perform as well psychometrically. 4 Several reviews evaluated ultra-short depression screeners, such as the Distress Thermometer (DT). 7, 38, 45, 47 Despite not specifically targeting depression, the DT showed good sensitivity and specificity as a depression screener and had high clinical acceptability in one review, 7 and good sensitivity to change in another. 4 Its performance also appeared comparable to the Brief Symptom Inventory-18 items (BSI-18) and General Health Questionnaire-12 items (GHQ-12) in palliative care. 8 However, given the potential high rates of false-negatives when using the DT, one review recommended the DT (and other ultra-short tools) not be used in isolation for depression screening. 7 Three reviews highlighted positive features of the Zung Self-Rating Depression Scale (ZSDS) (including being able to assess mood variation and having predictive validity data available). 8, 42, 43 However, one review reported that it had good specificity, but poor sensitivity, at the time of cancer diagnosis. 8 The Patient Health Questionnaire-9 (PHQ-9) was also evaluated by three reviews. 4, 5, 42 Vodermeier and colleagues 4 recognized its strong psychometric properties in medical populations, however rated it poorly due to low reliability and validity in cancer patients. Nelson and colleagues argued that the recall length of two weeks makes it less useful, for geriatrics in particular. 42 Some PHQ-9 questions were highlighted as less appropriate for those undergoing active treatment (ie, in regards to sleep, fatigue, appetite, concentration, and restlessness).
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Three reviews provided a positive appraisal of the Edinburgh Depression Scale (EDS) or the Brief Edinburgh Depression Scale (BEDS). 1, 4, 8 In palliative care, one review recommended the EDS due to the absence of somatic items, 1 with another arguing that the EDS can perform better than the HADS in this population. 4 The Center for Epidemiologic Studies Depression Scale (CES-D) was evaluated by two reviews. 4, 42 It was the highest ranked short tool in one review (particularly the negative affect subscale). 4 Although comprehensively evaluated, Nelson and colleagues argued that it was less suitable for geriatric patients because it includes only two of the most common seven depression symptoms in geriatric patients.
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One review described the General Health Questionnaire-28 (GHQ-28) as 'excellent' due to its high sensitivity and specificity, however the authors also expressed concerns about its length. 4 Despite its good screening performance, one review expressed caution regarding its use during active treatment because of a lack of validation studies. 8 The 12-item version of the GHQ (GHQ-12) was reviewed as 'good' by Thekkumpurath and colleagues, 1 although they reported it had inferior psychometric properties to the HADS in advanced cancer. Few studies have reported GHQ-12 parameters, making it difficult to compare with other tools. 1 The screening performance of the remaining scales was assessed in too few reviews to draw conclusions regarding their usefulness.
Case-finding
Evidence for the case-finding performance of depression measures was rare and less convincing, with only three reviews evaluating case-finding performance. One review assessed the HADS alone, 44 while two compared the performance of multiple measures. 7, 43 Mitchell and colleagues (2010) reported that all HADS subscales had poor case-finding utility indices (ranging from 0·27-0·29). 44 The remaining reviews reported moderate case-finding indices for the HADS. 7, 43 However, while the HADS indices were higher than the DT indices in both reviews, 7,43 they were lower than that calculated for the BDI-II, which was graded as having mid-level evidence for case-finding capacity. 7 Few data were available regarding the case-finding performance of depression measures for different populations or at different treatment stages, however there was some evidence that the BDI-18 did not perform as an effective case-finder in palliative care. 7, 43 Responsiveness One review assessed the capacity of depression measures to detect treatment effects after participation in randomized controlled trials of psychological interventions.
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The CES-D, the HADS, and the POMS-SF received the highest weighted scores (out the 16 measures assessed). The CES-D was most highly endorsed for studies in which depression was the sole focus, with an average detected effect size of -0·27
(ranging from -0·36 to -1·04). The length of the CES-D (20 items) was highlighted as a limitation. The HADS was the best supported measure if the study had a broader 11 focus, such as for studies also assessing anxiety, mixed affective disorders or general distress. In these studies, the detected depression effect sizes averaged 0·45 (range 0·1 to 0·97). HADS was however, considered less suitable for detecting minor depression. 5 The POMS-37 received a good score (ranked third) due to its good validity and reliability, although the reviewers highlighted that both the HADS and POMS-SF may be less suitable than the CES-D because they rely more heavily on anhedonia.
Consensus and discordance between reviews (Step 5: Interpreting the evidence 27 ) Table 8 For example, multiple reviews highlighted the benefits associated with the popularity of the HADS (for cross comparisons), 6, 8 and agreed that the variability of recommended HADS cut-points was a limitation. 4, 8, 19, 22, 46 Several reviews also agreed that the HADS was less well suited for palliative care and advanced cancer patients. 1, 8, 44 There were insufficient independent reviews of the case-finding ability and responsiveness of depression measures to identify consensus between reviews.
There were several disagreements between reviews regarding screening. When considering the HADS for example, it was unclear which scale or subscale (HADS-T, HADS-D or HADS-A) was most suitable, particularly since different reviews assessed one, or each of the scales/subscales. 7 Regarding the BDI and the CES-D, each was described as potentially useful for older, terminally ill patients, 11 yet were also highlighted as less suitable for this population. 42 The remaining measures were assessed by too few reviews to enable the identification of any disagreements regarding their suitability for screening, case finding, and detecting change.
Discussion
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In conducting this meta-review, the IPOS Research Committee hoped to ensure that investigators are utilizing the best performing measures, encourage consistency across data collection and reporting, and create future opportunities for cross-study comparisons. However, depression measures that were commonly recommended by some reviews were criticized by others. 4, 20 No review provided unqualified support for the adoption of any measure, and there were no measures identified as ideal for all types of patients and time points. The HADS was most often considered an acceptable depression screener and was most thoroughly evaluated, 1, 4, 7, 8, 44 although it remains unclear whether the HADS-D, HADS-T, or even the HADS-A, is the best choice. 44 Some captured reviews also recommended the CES-D, both for screening, 4, 5 and for detecting change. 5 Reviews assessing case-finding capacity were rare, with the BDI-II being recommended if no verbal assessment is possible. 7 Panel B places these findings into context.
This meta-review identified several measures as having particular potential for specific time points/populations. In palliative settings, the EDS (or BEDS) and the DT appear promising. 1, 8 The HADS appears less useful in this population, due to its focus on anhedonia, 5 although generally the HADS is appraised positively because of its reduced reliance on somatic symptoms. 20 Interestingly, there is some evidence to suggest that omitting somatic symptoms from depression screeners does not significantly improve the performance of common depression measures. 7, 49 Despite many published studies attributing disappointing findings to floor or ceiling effects, 50 the captured reviews did not address the risk of floor/ceiling effects in each measure. This is a significant limitation of many fixed length tools that might be overcome by computer adaptive testing (CAT). Given their recent development however, this meta-review failed to capture reviews of CAT measures of 43, 44 given that no patient-report measure has 100%
concordance with clinical interview 15, 60 and that most guidelines recommend screening should be used in conjunction with thorough clinical assessment anyway. 1, 6, 32, 44 Finally, given the often significant overlap between depression symptoms and other outcomes (such as distress, anxiety, fatigue, and pain), multidimensional assessment 63 suggesting that there still is a role for depression-specific measurement when it is the primary focus of a research project.
Future research
Further studies providing head-to-head (within sample) comparisons between measures and in comparison to clinical interviews are needed. There is a dearth of research assessing depression measures' case-finding ability and responsiveness.
Further work is needed to investigate the practical usefulness and clinical acceptability of depression measures. For many patients, depression may not be their primary concern, with practical needs, such as support with financial difficulties, and family and social concerns, often being more highly endorsed as core concerns for patients than depression. 7, 34, 59 Recent research also suggests that that anxiety may be of greater importance to patients than depression, especially for cancer survivors.
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The most useful screeners therefore might have a broader focus, beyond depression, and may also benefit from an assessment of patients' desire for help with the concerns they endorse.
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Additional population-specific work is also warranted. Some groups are more likely to under-report depression (eg, older patients, patients from different cultures, and those whose primary language is not English), meaning that measure performance may vary across groups. 11, 42 One review reported that two-thirds of their reviewed studies did not report the race/ethnicity of their sample, or specifically targeted a homogenous English-speaking sample, highlighting the literature dearth in this area. 34 Furthermore, recorded depression prevalence varies widely among patients with different tumor types, with patients with some cancers (eg, breast, head and neck, and malignant melanoma) reporting high depression levels, despite often greater needs in patients with other diseases (eg, lung cancer). 66 Indeed, there may be little conceptual or statistical equivalence between the same measures used in different populations, 34 putting some groups at risk of receiving inappropriate services if screening programs are used to determine access. 6 ,34
Meta-review limitations
Meta-reviews can overlook newly published papers. 27 The fact that CAT measures
were not captured demonstrates that there may be newer, but well-validated, measures that have not yet generated enough research to have been captured in a review. 27, 67 The PHQ-9 is another good example, because while it was reviewed less favourably in this meta-review, recent research suggests it may be a promising screener 12 and case-finder, 68 and may be quite responsive. 69 The captured reviews also provided different data and used different methods, making it difficult to draw firm conclusions, however future meta-reviews could utilize more sophisticated tools (such as Rasch measurement) to allow a common metric to be generated for different depression measures. 70 There were also overlaps in some of the captured reviews, which may have meant that the views of some, more prolific, research groups were over-represented. 27 Failure to capture non-English reviews was also a limitation.
Conclusion
Patient-report outcome measures can play an important role in cancer care, and when used appropriately, can serve as a cost-effective, equitable means of identifying patients in need of clinical assessment and treatment. 4, 6 Given that current clinician and researcher choice of depression measures can be arbitrary (based on popularity, familiarity, personal preference, or perceived relevance), 8 there is a need for more consensus on optimal depression measures in cancer. 5, 20 It is not likely, however, that a single tool exists, or will be developed, that meets the needs of every clinical and research purpose. 
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Added value of this study
This meta-review integrates the findings of all reviews about depression measure selection in cancer, published in the last 15 years. It identifies consensus and disagreements across reviews and provides guidance about the most, and least, recommended measures, organized by study goal and target population.
Implications of all the available evidence
No currently available depression measure performs well enough to meet the needs of every clinical practice or research study. It is critical that if investigators choose to undertake depression screening or case-finding, they utilize the best available measure for their population and study design while being cognizant of their limitations. In doing so, depression measurement will become more accurate and consistent. Improved awareness of measure limitations will facilitate a more sophisticated interpretation of the data provided by patient-report depression tools. *recommended/cautioned against by one review; **recommended/cautioned against by two reviews; ***recommended/cautioned against by three or more reviews. HADS-D= Hospital Anxiety and Depression Scale-Depression subscale. HADS=Hospital Anxiety and Depression Scale. HADS-A= Hospital Anxiety and Depression Scale-Anxiety subscale. BDI=Beck Depression Inventory. DT=Distress Thermometer. CES-D=Center of Epidemiologic Studies-Depression. GHQ-28=General Health Questionnaire-28 items. BEDS=Brief Edinburgh Depression Scale. EDS=Edinburgh Depression Scale. BDI-II=Beck Depression Inventory-II. ZSDS=Zung Self-rating Depression Scale. POMS-37=Profile of Mood States-37 items. PHQ-9=Patient Health Questionnaire-9 items. MHI-38=Mental Health Inventoru-38 items. *recommended/cautioned against by one review; **recommended/cautioned against by two reviews; ***recommended/cautioned against by three or more reviews.
HADS=Hospital Anxiety and Depression Scale. EDS=Edinburgh Depression Scale. DT=Distress Thermometer. BDI=Beck Depression Inventory. ZSDS=Zung Self-rating Depression Scale. Note: 'HADS' has been used to refer to 'HADS-A', 'HADS-D' and 'HADS-T' *where the threshold was found in only 1 study, the range from the study was reported where possible. Table 3 . Measures for depression screening: Reviews meeting at least 20 PRISMA criteria Table 5 . Detailed summary of reviews of measures used to detect change in interventions meeting a minimum of 20 criteria outlined in the PRISMA Statement. Results of the review suggest a threshold of 8 to achieve high sensitivity, and lowering to 5 for some cancer populations.
Although HADS-D appears to be quite useful, it is suggested that no single tool can be used across treatment and disease pathway. Screening methods should be adapted according to location of assessment, stage of cancer (eg, use of HADS is not recommended in palliative care) and diagnosis.
HADS-D=Hospital Anxiety and Depression Scale-Depression subscale. HADS=Hospital Anxiety Depression Scale Table 6 . General findings of recommendation reviews meeting fewer than 20 criteria outlined in the PRISMA Statement. Provides a summary of patient-report screening tools used for psychological distress in women with breast cancer. Evaluated the psychometric properties and provided pros and cons of each measure.
Found BDI-SF most appropriate tool to use to detect depression in a clinical setting. BSI-18 and GHQ-12 also recommended, although GHQ-12 has not widely been used in cancer groups. Although CES-D has been widely used in cancer populations, it has limitations as a suitable choice for a screening tool. Similarly, HADS might not be suitable for screening for depression.
The most suitable screening tool will depend on the intended use. BDI-SF was considered the most suitable screening tool to detect depression in a clinical setting. Provides a narrative guide to the use of commonly used outcome measures in psycho-oncology.
BDI described as widely used with cancer patients, although it contains some somatic items which may affect scores. BDI-II described as having 'good performance', easy to use, quick to complete and less emphasis on somatic symptoms. CES-D described as growing in popularity, with good validity/reliability in specific cancer patients (eg, breast). HADS has least focus on somatic symptoms.
BDI, CES-D and HADS may all be reasonable depression screening measures in ambulatory cancer patients.
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